Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
87 studies found for:    mRCC
Show Display Options
Rank Status Study
1 Recruiting Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
Condition: Complete Remission in Renal Cell Carcinoma
Intervention: Drug: sunitinib
2 Completed Sorafenib in Elderly mRCC
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
3 Unknown  Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
Conditions: Self Efficacy;   Adverse Drug Event;   Carcinoma, Renal Cell
Intervention: Drug: pazopanib
4 Recruiting Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Conditions: Metastatic Renal Cell Carcinoma;   RCC
Interventions: Drug: Ixazomib;   Drug: Pegylated IFN-alpha 2b
5 Recruiting A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
Condition: Stage IV Renal Cell Cancer AJCC V7
Interventions: Drug: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
6 Active, not recruiting Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Conditions: Genitourinary Cancer;   Kidney Cancer
Interventions: Drug: Sunitinib;   Behavioral: Questionnaire
7 Recruiting Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
Condition: Renal Cell Carcinoma, Metastatic
Interventions: Biological: Intuvax;   Drug: Sunitinib
8 Withdrawn Functional Imaging in the Assessment of mRCC Response to Sunitinib
Condition: Metastatic Renal Cell Carcinoma
Intervention: Other: Magnetic Resonance Imaging (MRI)
9 Completed
Has Results
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: SUTENT
10 Active, not recruiting Sequential Therapy With Bevacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carinoma (mRCC)
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Avastin in combination with Roferon-A;   Drug: Afinitor;   Drug: Sutent, Nexavar or Votrient
11 Recruiting Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Condition: Metastatic Renal Cell Carcinoma (mRCC)
Intervention: Other: observational
12 Completed Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Condition: Metastatic Renal Cell Carcinoma (mRCC)
Intervention: Drug: Everolimus
13 Recruiting Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Conditions: Carcinoma, Renal Cell, Advanced;   Lymphoma, Mantle-Cell;   Gastrointestinal Stroma Tumors
Interventions: Drug: Temsirolimus;   Drug: Sunitinib;   Drug: Axitinib
14 Recruiting INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients
Conditions: Glioblastoma Multiforme;   Gliosarcoma;   Colorectal Cancer;   Renal Cell Carcinoma
Interventions: Drug: INC280;   Biological: bevacizumab
15 Completed
Has Results
Sutent Rechallenge In mRCC Patients
Condition: Metastatic Renal Cell Carcinoma
Intervention: Other: sunitinib: observational study
16 Terminated Cost Effectiveness Of Sunitinib In Central America And Caribbean
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib
17 Completed
Has Results
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Condition: Carcinoma, Renal Cell
Intervention: Drug: AG-013736
18 Recruiting Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Condition: Kidney Cancer
Interventions: Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Ipilimumab
19 Active, not recruiting Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
Condition: Renal Cell Carcinoma (RCC)
20 Unknown  Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Interleukin-2;   Drug: Interferon Alfa-2b;   Drug: Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.